Heart pump patients under the microscope: new study tracks Long-Term survival
NCT ID NCT07382284
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study follows 300 adults with end-stage heart failure who receive a left ventricular assist device (LVAD) as part of their standard care. Researchers will track survival, complications, and hospital readmissions for 3-5 years. They will also study heart tissue and blood samples to find biological clues that may predict how well patients do. No experimental treatments are involved—this is purely an observation to learn more about long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
+86 025 83106666
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.